Sihuan Pharmaceutical Holdings Group Ltd. is a leading pharmaceutical company based in China with a medium ESG risk rating score of 29.6. Specializing in the research, development, manufacturing, and sale of pharmaceutical products, the company's portfolio includes treatments for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. With three reportable segments focusing on medical aesthetic products, innovative medicine, and generic medicine, Sihuan Pharmaceutical Holdings Group Ltd. generates the majority of its revenue from Mainland China and the United States. The company's commitment to sustainability and governance makes it a responsible choice for investors.